M. Bohl-Bühler

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial

I.‐H. Song, Hildrun Haibel, C Althoff et al. · Annals of the Rheumatic Diseases · 2011 · 286 citations · Full text

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial

In‐Ho Song, Christian E. Althoff, Hildrun Haibel et al. · Annals of the Rheumatic Diseases · 2012 · 93 citations

Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey

Jane Zochling, M. Bohl-Bühler, Xenofon Baraliakos et al. · Clinical Rheumatology · 2006 · 68 citations

Inflammation, Rheumatology, Anti-inflammatory +7

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany

Klaus Krüger, Gerd R Burmester, Siegfried Wassenberg et al. · BMJ Open · 2018 · 41 citations · Full text

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany

Klaus Krüger, Gerd R Burmester, Siegfried Wassenberg et al. · Rheumatology International · 2018 · 25 citations · Full text